PI3K-specific inhibitors have been developed, and the first PI3K inhibitor, selective for p110δ, has entered the clinic for treatment of blood cancers (14, 96), and other PIK3CD-specific inhibitors have showed efficacy in the treatment of APDS (97, 98). This evidence concerns the gene PIK3CA and hematopoietic and lymphoid system neoplasm.